MGC Pharmaceuticals has reported record sales for March from its pharmaceutical grade phytomedicine products, its MP product line in Australia driving the company’s best monthly result to date with more than 1,500 units sold.

Global chief sales officer Nicole Godresse said: “In recent months we have seen rapid sales growth of our medical cannabis products as a direct result of our strategy to broaden our core prescriber base, diversify and expand our revenue streams and build additional strategic alliances.

“It is pleasing to see these strategies starting to translate into positive commercial outcomes and we expect this strong growth momentum to continue in 2021 and beyond.”

Leave a comment

Your email address will not be published. Required fields are marked *